

# CPTC-TERF2-1 (CAB080269)

**Uniprot ID:** Q15554

**Protein name:** TERF2\_HUMAN

**Full name:** Telomeric repeat-binding factor 2

**Tissue specificity:** Ubiquitous. Highly expressed in spleen, thymus, prostate, uterus, testis, small intestine, colon and peripheral blood leukocytes.

**Function:** Binds the telomeric double-stranded 5'-TTAGGG-3' repeat and plays a central role in telomere maintenance and protection against end-to-end fusion of chromosomes. In addition to its telomeric DNA-binding role, required to recruit a number of factors and enzymes required for telomere protection, including the shelterin complex, TERF2IP/RAP1 and DCLRE1B/Apollo. Component of the shelterin complex (telosome) that is involved in the regulation of telomere length and protection. Shelterin associates with arrays of double-stranded 5'-TTAGGG-3' repeats added by telomerase and protects chromosome ends; without its protective activity, telomeres are no longer hidden from the DNA damage surveillance and chromosome ends are inappropriately processed by DNA repair pathways. Together with DCLRE1B/Apollo, plays a key role in telomeric loop (T loop) formation by generating 3' single-stranded overhang at the leading end telomeres: T loops have been proposed to protect chromosome ends from degradation and repair. Required both to recruit DCLRE1B/Apollo to telomeres and activate the exonuclease activity of DCLRE1B/Apollo. Preferentially binds to positive supercoiled DNA. Together with DCLRE1B/Apollo, required to control the amount of DNA topoisomerase (TOP1, TOP2A and TOP2B) needed for telomere replication during fork passage and prevent aberrant telomere topology. Recruits TERF2IP/RAP1 to telomeres, thereby participating in to repressing homology-directed repair (HDR), which can affect telomere length.

**Subcellular location:**

Nucleus (*match to sequence model, experimental evidence*)


Chromosome > Telomere (*experimental evidence*)

**NOTE:** Colocalizes with telomeric DNA in interphase cells and is located at chromosome ends during metaphase.

**Protein existence:** Experimental evidence at protein level


**Comment:**

## Immunohistochemistry




<b>IHC protocol:</b>	HIER pH6, Dilution 1:600
<b>IHC test staining:</b>	Cytoplasmic positivity in testis.
<b>Literature conformance:</b>	Not consistent with gene/protein characterization data
<b>Literature significance:</b>	
<b>RNA similarity:</b>	Very low consistency between antibody staining and RNA expression data
<b>RNA tissue specificity:</b>	Low tissue specificity
<b>RNA tissue distribution:</b>	Detected in all
<b>IHC Sibling similarity:</b>	Other antibody shows dissimilar IHC staining pattern
<b>IHC fail comment:</b>	ANTIBODY FAILED: Not consistent with RNA

## Immunofluorescence



<b>IF Overlay:</b>	antibody (green), anti-tubulin (red) and DAPI (blue)
<b>IF main location:</b>	Cytosol - 12: <b>Uncertain</b> (auto)
<b>IF additional location:</b>	Nucleoplasm - 3: <b>Supportive</b> (auto)
<b>IF approved for publication on HPA:</b>	No
<b>IF in THP-1:</b>	Nucleoplasm Cytosol
<b>IF in U-2 OS:</b>	Cytosol

# Western blot



<b>WB Size markers (kDa):</b>	250, 130, 100, 70, 55, 35, 25, 15, 10
<b>WB Lanes:</b>	Marker (1), RT4 (2), U-251 MG (3), Plasma (4), Liver (5), Tonsil (6)
<b>WB Target weight (kDa):</b>	6, 10, 15, 23, 27, 32, 32, 60
<b>WB Validation:</b>	Uncertain (Single band differing more than +/-20% from predicted size in kDa and not supported by experimental and/or bioinformatic data.)